Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases
Corvus Pharmaceuticals (NASDAQ: CRVS) announced the publication of preclinical data in Science Signaling, demonstrating the potential of ITK inhibition with soquelitinib for treating inflammatory diseases. The study, conducted by Cornell University researchers, showed that ITK inhibition induces switching of proinflammatory Th17 cells into anti-inflammatory Treg cells, both in vitro and in vivo.
Key findings include:
- Dose-dependent inhibition of Th17 cell differentiation and increase in Foxp3+ Treg cells
- Switched Foxp3+ Treg cells suppress naïve T cell proliferation
- Significant reduction of Th17 cells in the lung in a mouse model of allergic airway inflammation
This research supports Corvus' view on the broad potential of ITK inhibition for treating autoimmune, allergic, and inflammatory diseases.
Corvus Pharmaceuticals (NASDAQ: CRVS) ha annunciato la pubblicazione di dati preclinici su Science Signaling, dimostrando il potenziale dell'inibizione di ITK con soquelitinib per il trattamento delle malattie infiammatorie. Lo studio, condotto da ricercatori della Cornell University, ha mostrato che l'inibizione di ITK induce la trasformazione delle cellule proinfiammatorie Th17 in cellule Treg anti-infiammatorie, sia in vitro che in vivo.
I risultati chiave includono:
- Inibizione dose-dipendente della differenziazione delle cellule Th17 e aumento delle cellule Treg Foxp3+
- Cellule Treg Foxp3+ trasformate sopprimono la proliferazione delle cellule T naive
- Significativa riduzione delle cellule Th17 nei polmoni in un modello murino di infiammazione allergica delle vie aeree
Questa ricerca supporta la visione di Corvus sul ampio potenziale dell'inibizione di ITK nel trattamento di malattie autoimmuni, allergiche e infiammatorie.
Corvus Pharmaceuticals (NASDAQ: CRVS) anunció la publicación de datos preclínicos en Science Signaling, demostrando el potencial de la inhibición de ITK con soquelitinib para tratar enfermedades inflamatorias. El estudio, realizado por investigadores de la Universidad de Cornell, mostró que la inhibición de ITK induce el cambio de células Th17 proinflamatorias a células Treg antiinflamatorias, tanto in vitro como in vivo.
Los hallazgos clave incluyen:
- Inhibición dependiente de la dosis de la diferenciación de células Th17 y aumento de células Treg Foxp3+
- Células Treg Foxp3+ cambiadas suprimen la proliferación de células T naïve
- Reducción significativa de células Th17 en los pulmones en un modelo de ratón de inflamación alérgica de las vías respiratorias
Esta investigación apoya la visión de Corvus sobre el amplio potencial de la inhibición de ITK para tratar enfermedades autoinmunes, alérgicas e inflamatorias.
코르부스 제약(Corvus Pharmaceuticals)(NASDAQ: CRVS)는 Science Signaling에 전임상 데이터 발표를 발표, 소켈리틴(Foxp3+)을 통한 ITK 억제의 잠재력을 염증 질환 치료에 demonstrated하였습니다. 코넬 대학교 연구자들이 수행한 이 연구는 ITK 억제가 프로염증성 Th17 세포를 항염증성 Treg 세포로 전환시킨다는 것을 보여주었습니다. 실험실 내(in vitro) 및 생체 내(in vivo)에서 확인되었습니다.
주요 발견 사항은:
- Th17 세포의 차별화에 대한 용량-의존적 억제 및 Foxp3+ Treg 세포의 증가
- 전환된 Foxp3+ Treg 세포가 순수 T 세포의 증식을 억제함
- 알레르기 기관지 염증의 마우스 모델에서 폐에 있는 Th17 세포의 유의미한 감소
이 연구는 자가면역, 알레르기 및 염증 질환 치료를 위한 ITK 억제의 광범위한 잠재력에 대한 코르부스의 관점을 지지합니다.
Corvus Pharmaceuticals (NASDAQ: CRVS) a annoncé la publication de données précliniques dans Science Signaling, démontrant le potentiel de l'inhibition de l'ITK avec soquelitinib pour traiter les maladies inflammatoires. L'étude, menée par des chercheurs de l'Université Cornell, a montré que l'inhibition de l'ITK induit le passage de cellules Th17 pro-inflammatoires en cellules Treg anti-inflammatoires, tant in vitro qu'in vivo.
Les principales conclusions incluent :
- Inhibition dépendante de la dose de la différenciation des cellules Th17 et augmentation des cellules Treg Foxp3+
- Les cellules Treg Foxp3+ transformées suppriment la prolifération des cellules T naïves
- Réduction significative des cellules Th17 dans les poumons dans un modèle murin d'inflammation allergique des voies respiratoires
Cette recherche soutient la vision de Corvus sur le large potentiel de l'inhibition de l'ITK pour traiter les maladies auto-immunes, allergiques et inflammatoires.
Corvus Pharmaceuticals (NASDAQ: CRVS) gab die Veröffentlichung vorklinischer Daten in Science Signaling bekannt, die das Potenzial der ITK-Hemmung mit Soquelitinib zur Behandlung von Entzündungskrankheiten demonstrieren. Die Studie, die von Forschern der Cornell University durchgeführt wurde, zeigte, dass die ITK-Hemmung proinflammatorische Th17-Zellen in antiinflammatorische Treg-Zellen umschaltet, sowohl in vitro als auch in vivo.
Wichtige Ergebnisse umfassen:
- Dosisabhängige Hemmung der Differenzierung von Th17-Zellen und Erhöhung von Foxp3+ Treg-Zellen
- Umschaltende Foxp3+ Treg-Zellen unterdrücken die Proliferation naiver T-Zellen
- Signifikante Reduktion von Th17-Zellen in der Lunge in einem Mausmodell allergischer Atemwegentzündung
Diese Forschung unterstützt die Auffassung von Corvus über das breite Potenzial der ITK-Hemmung zur Behandlung autoimmune, allergische und entzündliche Erkrankungen.
- Publication in peer-reviewed journal Science Signaling validates the potential of ITK inhibition
- Preclinical data demonstrates dual-effect mechanism: decreasing inflammatory Th17 cells and increasing anti-inflammatory Treg cells
- Soquelitinib showed efficacy in reducing inflammation in an in vivo asthma model
- Research supports potential applications in autoimmune, allergic, and inflammatory diseases
- None.
This publication in Science Signaling represents a significant advancement in understanding the mechanism of action of ITK inhibition, particularly with soquelitinib. The data provides compelling evidence for the potential of ITK inhibitors in treating inflammatory diseases, which could have far-reaching implications for Corvus Pharmaceuticals.
Key findings include:
- ITK inhibition induces a switch from proinflammatory Th17 cells to anti-inflammatory Treg cells
- Soquelitinib demonstrated dose-dependent inhibition of Th17 cell differentiation and increased Foxp3+ Treg cells
- In vivo studies showed reduced inflammation in an asthma model by increasing the Treg to Th17 cell ratio in the lungs
These results are particularly exciting as they suggest a dual mechanism of action: not only reducing inflammatory cells but also increasing anti-inflammatory cells. This could potentially lead to more effective treatments for a range of autoimmune, allergic and inflammatory diseases.
However, it's important to note that these are preclinical results. While promising, further clinical studies will be necessary to confirm these effects in humans and establish safety and efficacy profiles. The translation from animal models to human patients is not always straightforward, especially in complex immune-mediated diseases.
Nevertheless, this publication in a prestigious journal by respected researchers at Cornell University lends significant credibility to Corvus' approach and may attract increased attention from both the scientific community and potential investors or partners in the pharmaceutical industry.
From a financial perspective, this preclinical data publication is a positive development for Corvus Pharmaceuticals (NASDAQ: CRVS). While it doesn't directly impact current revenues, it significantly enhances the company's intellectual property and potential market value.
Key financial implications include:
- Increased validation of Corvus' research direction, potentially attracting more investor interest
- Enhanced potential for partnerships or licensing agreements with larger pharmaceutical companies
- Possible expansion of the addressable market for soquelitinib beyond its current oncology and immunology indications
- Potential for increased R&D investment to accelerate development in inflammatory disease indications
However, investors should be cautious. Despite the promising results, the path from preclinical studies to marketable drugs is long, expensive and risky. Many promising candidates fail in later-stage clinical trials or face regulatory hurdles.
Additionally, while this news might lead to a short-term boost in stock price, the long-term financial impact will depend on successful clinical trials and eventual commercialization. Corvus will likely need to secure additional funding to support expanded clinical programs, which could lead to dilution for current shareholders.
In conclusion, while this news strengthens Corvus' position in the competitive biotech landscape, investors should view it as a positive step in a long journey rather than an immediate game-changer for the company's financial position.
Data demonstrated in vitro and in vivo ITK inhibition with soquelitinib induced switching of proinflammatory Th17 cells into anti-inflammatory Treg cells
Publication confirms and extends understanding of ITK inhibition mechanism of action and its potential in inflammatory autoimmune and allergic diseases
Data published by leading researchers from Cornell University in peer-reviewed journal Science Signaling
BURLINGAME, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced data published by leading researchers from Cornell University (Cornell) in Science Signaling, a peer-reviewed journal, that further corroborates Corvus’ views of the potential of ITK inhibition as a novel approach to treating inflammatory diseases. Researchers at Cornell utilized soquelitinib (formerly CPI-818), the Company’s selective ITK inhibitor, to demonstrate in vitro and in vivo that ITK inhibition induces switching of proinflammatory Th17 cells into anti-inflammatory Treg suppressor cells. The article states “The findings of this study provide greater insight into how ITK controls the Th17 and Treg dichotomy, and these findings could have broader implications for immune disorders with an imbalance of Th17 and Treg.”
“The results published by the Avery Lab at Cornell University expands upon our knowledge of the mechanism of action of ITK inhibition in immunology. The results confirm the broad potential for ITK inhibition to treat a range of indications,” said James Rosenbaum, M.D., senior vice president of research at Corvus. “Importantly, their data demonstrated that the mechanism has a dual-effect, decreasing inflammatory Th17 cells by converting them into anti-inflammatory Treg cells. This conversion is highly relevant for autoimmune, allergic and inflammatory diseases. This was elegantly demonstrated in an in vivo asthma model of allergic airway inflammation in which treatment with soquelitinib reduced inflammation by increasing the ratio of Treg to Th17 cells in the lungs.”
The article titled “The kinase ITK controls a Ca2+-mediated switch that balances Th17 and Treg cell differentiation” was published in the peer-reviewed journal Science Signaling and is available for viewing at DOI: 10.1126/scisignal.adh2381. The senior author is Avery August, Ph.D., Professor of Immunology, Department of Microbiology and Immunology at Cornell University College of Veterinary Medicine. Dr. August’s research group focuses on the tyrosine kinases in the regulation of the immune response and the role of intracellular signaling in regulating T cell differentiation and cytokine production, particularly inflammatory and anti-inflammatory cytokines.
Key results from the third-party preclinical studies described in the article demonstrated that soquelitinib had the following observed effects in vitro and in in vivo models of inflammatory disease:
- ITK controls the switch between Th17 and Foxp3+ Treg cells
- In in vitro experiments, ITK inhibition with soquelitinib results in dose dependent inhibition of Th17 cell differentiation along with an increase in Foxp3+ Treg cells
- Switched Foxp3+ Treg cells suppress naïve T cell proliferation and behave like true Treg cells
- Soquelitinib treatment of mice with allergic (house dust mite) airway inflammation significantly reduced the percentage of Th17 cells in the lung resulting in an increase in the ratio of Treg to Th17 cells
Corvus’ ITK inhibitors include soquelitinib, which was used in the preclinical studies described in the article, and several next-generation molecules that are being optimized [in preclinical studies] for use in a variety of inflammatory and immune disease indications. Soquelitinib is currently in clinical trials for oncology and immunology indications.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.
About Soquelitinib
Soquelitinib (formerly CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function. Based on interim results from a Phase 1/1b clinical trial in patients with refractory T cell lymphomas, which demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies, the Company plans to initiate a registrational Phase 3 clinical trial of soquelitinib in patients with relapsed PTCL. Soquelitinib also is now being investigated in a randomized placebo controlled phase 1 clinical trial in patients with atopic dermatitis. The immunologic effects of soquelitinib lead to what is known as Th1 skewing and inhibition of Th2 and Th17 cells. Research on soquelitinib’s mechanism of action suggests that it has the potential to control differentiation of normal T helper cells and enhance immune responses to tumors by augmenting the generation of cytotoxic killer T cells and the production of cytokines that inhibit cancer cell survival. Soquelitinib has also been shown to prevent T cell exhaustion, a major limitation of current immunotherapy and CAR-T therapies. Soquelitinib has been shown to affect T cell differentiation and induce the generation of Th1 helper cells while blocking the development of both Th2 and Th17 cells and production of their secreted cytokines. Th1 T cells are required for immunity to tumors, viral infections and other infectious diseases. Th2 and Th17 helper T cells are involved in the pathogenesis of many autoimmune and allergic diseases. The Company believes the inhibition of specific molecular targets in T cells may be of therapeutic benefit for patients with cancers, including solid tumors, and in patients with autoimmune and allergic diseases.
Forward-Looking Statements
This press release contains forward-looking statements, including statements related to the potential efficacy of the Company’s product candidates including soquelitinib; and the broad potential of soquelitinib to treat a variety of indications. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2024, filed with the Securities and Exchange Commission on May 7, 2024, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of soquelitinib and its other product candidates; the results of preclinical studies, including preclinical studies conducted by third-parties using the Company’s product candidates, and interim data from clinical trials not being predictive of future results; the Company’s ability to enroll sufficient numbers of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States, and other foreign countries; and the costs of clinical trials may exceed expectations. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
![](https://ml.globenewswire.com/media/ZDc3MjQ2NDMtMGRiMC00YjA0LTliMzgtMDM5ZGQxN2RjYzU2LTEwMzc1NjU=/tiny/Corvus-Pharmaceuticals-Inc-.png)
FAQ
What is the main finding of the Corvus Pharmaceuticals (CRVS) preclinical study on soquelitinib?
How did soquelitinib perform in the allergic airway inflammation model for Corvus Pharmaceuticals (CRVS)?
What are the potential applications of Corvus Pharmaceuticals' (CRVS) ITK inhibitors based on the preclinical data?